New medications for use in patients with rheumatoid arthritis
Identifieur interne : 002450 ( Main/Exploration ); précédent : 002449; suivant : 002451New medications for use in patients with rheumatoid arthritis
Auteurs : Kevin G. Moder [États-Unis]Source :
- Annals of Allergy, Asthma & Immunology [ 1081-1206 ] ; 2000.
English descriptors
- Teeft :
- Agents work, Antirheumatic drugs, Arthritis, Arthritis rheum, Asthma, Combination therapy, Common side effects, Comparative study, Data sources, Different mechanisms, Dmards, Dose corticosteroids, Etanercept, Fusion protein, Initial therapy, Interstitial lung disease, Intramuscular gold, Joint counts, Joint involvement, Laboratory parameters, Leflunomide, Liver transaminases, Loading dose, Many patients, Medication, Methotrexate, More experience, Necrosis, Necrosis factor, Nsaid, Nursing mothers, Ocular involvement, Oral loading dose, Oral methotrexate tablets, Oral tablets, Peripheral blood, Proc natl acad, Receptor, Rheum, Rheumatoid, Rheumatoid arthritis, Side effects, Significant response, Single agent, Synovial fluid, Tissue diseases, Transaminase, Tumor necrosis factor, Tumor necrosis factor receptor, Usual dose.
Abstract
Introduction Several new medications have become available to physicians for the treatment of patients with rheumatoid arthritis (RA).Learning objectives To familiarize the reader with these new medications, including their benefits and side effects.Data sources Data sources include published articles regarding the use of these medications. Study selection includes available information obtained from an online literature search (Mayo Search) regarding these agents, with additional information from the manufactures and our pharmacy.Conclusion The results of this review indicate that leftunomide (Arava) and etanercept (Enbrel) are useful new agents for treatment of patients with rheumatoid arthritis.
Url:
DOI: 10.1016/S1081-1206(10)62772-X
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 001C23
- to stream Istex, to step Curation: 001C23
- to stream Istex, to step Checkpoint: 001267
- to stream Main, to step Merge: 002478
- to stream Main, to step Curation: 002450
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title>New medications for use in patients with rheumatoid arthritis</title><author><name sortKey="Moder, Kevin G" sort="Moder, Kevin G" uniqKey="Moder K" first="Kevin G." last="Moder">Kevin G. Moder</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:6CCC6C0E4FE7B98CBDDA283B1B7342C2AFB017A4</idno><date when="2000" year="2000">2000</date><idno type="doi">10.1016/S1081-1206(10)62772-X</idno><idno type="url">https://api.istex.fr/ark:/67375/6H6-N5N5MS4S-8/fulltext.pdf</idno><idno type="wicri:Area/Istex/Corpus">001C23</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">001C23</idno><idno type="wicri:Area/Istex/Curation">001C23</idno><idno type="wicri:Area/Istex/Checkpoint">001267</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Checkpoint">001267</idno><idno type="wicri:doubleKey">1081-1206:2000:Moder K:new:medications:for</idno><idno type="wicri:Area/Main/Merge">002478</idno><idno type="wicri:Area/Main/Curation">002450</idno><idno type="wicri:Area/Main/Exploration">002450</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a">New medications for use in patients with rheumatoid arthritis</title><author><name sortKey="Moder, Kevin G" sort="Moder, Kevin G" uniqKey="Moder K" first="Kevin G." last="Moder">Kevin G. Moder</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><placeName><region type="state">Minnesota</region></placeName><wicri:cityArea>Division of Rheumatology, Department of Internal Medicine, Mayo Clinic, Rochester</wicri:cityArea></affiliation></author></analytic><monogr></monogr><series><title level="j">Annals of Allergy, Asthma & Immunology</title><title level="j" type="abbrev">ANAI</title><idno type="ISSN">1081-1206</idno><imprint><publisher>ELSEVIER</publisher><date type="published" when="2000">2000</date><biblScope unit="volume">84</biblScope><biblScope unit="issue">3</biblScope><biblScope unit="page" from="280">280</biblScope><biblScope unit="page" to="284">284</biblScope></imprint><idno type="ISSN">1081-1206</idno></series></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">1081-1206</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="Teeft" xml:lang="en"><term>Agents work</term><term>Antirheumatic drugs</term><term>Arthritis</term><term>Arthritis rheum</term><term>Asthma</term><term>Combination therapy</term><term>Common side effects</term><term>Comparative study</term><term>Data sources</term><term>Different mechanisms</term><term>Dmards</term><term>Dose corticosteroids</term><term>Etanercept</term><term>Fusion protein</term><term>Initial therapy</term><term>Interstitial lung disease</term><term>Intramuscular gold</term><term>Joint counts</term><term>Joint involvement</term><term>Laboratory parameters</term><term>Leflunomide</term><term>Liver transaminases</term><term>Loading dose</term><term>Many patients</term><term>Medication</term><term>Methotrexate</term><term>More experience</term><term>Necrosis</term><term>Necrosis factor</term><term>Nsaid</term><term>Nursing mothers</term><term>Ocular involvement</term><term>Oral loading dose</term><term>Oral methotrexate tablets</term><term>Oral tablets</term><term>Peripheral blood</term><term>Proc natl acad</term><term>Receptor</term><term>Rheum</term><term>Rheumatoid</term><term>Rheumatoid arthritis</term><term>Side effects</term><term>Significant response</term><term>Single agent</term><term>Synovial fluid</term><term>Tissue diseases</term><term>Transaminase</term><term>Tumor necrosis factor</term><term>Tumor necrosis factor receptor</term><term>Usual dose</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract">Introduction Several new medications have become available to physicians for the treatment of patients with rheumatoid arthritis (RA).Learning objectives To familiarize the reader with these new medications, including their benefits and side effects.Data sources Data sources include published articles regarding the use of these medications. Study selection includes available information obtained from an online literature search (Mayo Search) regarding these agents, with additional information from the manufactures and our pharmacy.Conclusion The results of this review indicate that leftunomide (Arava) and etanercept (Enbrel) are useful new agents for treatment of patients with rheumatoid arthritis.</div></front></TEI><affiliations><list><country><li>États-Unis</li></country><region><li>Minnesota</li></region></list><tree><country name="États-Unis"><region name="Minnesota"><name sortKey="Moder, Kevin G" sort="Moder, Kevin G" uniqKey="Moder K" first="Kevin G." last="Moder">Kevin G. Moder</name></region></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/ChloroquineV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002450 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 002450 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= ChloroquineV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:6CCC6C0E4FE7B98CBDDA283B1B7342C2AFB017A4
|texte= New medications for use in patients with rheumatoid arthritis
}}
| This area was generated with Dilib version V0.6.33. |  |